Trends in Mortality Involving Coexisting Lung Cancer and Chronic Kidney Disease in the United States: A CDC WONDER Analysis, 1999–2024
This CDC WONDER analysis reveals that from 1999 to 2024, mortality involving coexisting lung cancer and chronic kidney disease among U.S. adults aged 45 and older increased nationally with significant disparities across age, sex, race, and geography, highlighting the need for targeted public health interventions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human body as a bustling, high-tech city. In this city, the lungs are the massive air filtration plants, constantly swapping fresh air for used air, while the kidneys are the sophisticated water treatment facilities, scrubbing toxins from the bloodstream to keep everything clean. Sometimes, these two critical systems face trouble at the same time. When a city's air filters start failing due to a nasty invader like cancer, and the water treatment plant is already struggling with chronic wear and tear, the whole city gets into a very tricky situation. This isn't just about one broken machine; it's about how the failure of one system makes the other one work even harder, often leading to a crisis that is harder to manage than if either problem existed alone. Scientists have long known that lung cancer is a leading cause of death and that kidney disease is a major health burden, but they haven't fully mapped out what happens when these two specific problems show up together on the same death certificate over a long period. They wanted to know: as the years go by, is this "double trouble" getting better, worse, or staying the same? And are some neighborhoods or groups of people hit harder than others?
This paper acts like a giant, 26-year-long detective story, sifting through millions of records from the Centers for Disease Control and Prevention (CDC) to track down exactly how many people in the United States died with both lung cancer and chronic kidney disease listed on their death certificates between 1999 and 2024. The researchers focused on adults aged 45 and older, because that's when these conditions usually start showing up. They didn't just count the bodies; they looked at the patterns, asking questions like: Did the number of these "double trouble" deaths go up or down? Did it happen faster in some years than others? And who was most likely to be in this dangerous situation?
The investigation revealed a surprising and somewhat worrying trend. While lung cancer deaths on their own have been going down (thanks to better treatments and detection), and kidney disease deaths have been slowly creeping up, the number of deaths involving both conditions together actually increased over the study period. It's as if the city's air filters and water plants are getting into a vicious cycle where the combination is becoming more deadly. The data shows that the overall rate of these deaths rose from 0.70 per 100,000 people in 1999 to 1.50 per 100,000 in 2024. That's more than double the rate.
The story gets even more specific when you look at when these changes happened. The researchers used a special statistical tool called "Joinpoint regression" to find the turning points in the timeline. They found that the rate stayed pretty steady from 1999 to 2008. Then, between 2008 and 2011, there was a sudden, sharp spike—like a rocket shooting up. After that, there was a brief dip between 2011 and 2014, but then the numbers started climbing again steadily through 2024. It wasn't a smooth, straight line up; it was a jagged path with a dramatic jump in the middle.
The paper also highlights that this "double trouble" doesn't affect everyone equally. It's like a storm that hits some parts of the city harder than others. The data shows that older adults (65 and up) faced a much higher risk than middle-aged adults. Men were consistently more likely to die with these conditions than women. Race and ethnicity played a huge role too: non-Hispanic Black individuals had the highest mortality rates throughout the entire period, while Hispanic individuals had the lowest. Geography mattered just as much; people living in the Midwest and the South, particularly in states like Kentucky, West Virginia, and Mississippi, faced higher death rates than those in the West. Interestingly, people living in non-metropolitan (rural) areas had higher death rates than those in big cities, suggesting that maybe it's harder to get the specialized care needed to manage two complex diseases when you live far from a major hospital.
The authors are careful to say that while they found these clear patterns, they can't prove exactly why the numbers went up. They suggest it might be a mix of things: people living longer with cancer (so they have more time to develop kidney issues), the rising rates of diabetes and high blood pressure that hurt kidneys, and perhaps even changes in how doctors fill out death certificates to list these conditions. They also note that the COVID-19 pandemic might have messed with healthcare access in the later years, adding another layer of complexity.
Ultimately, this paper doesn't offer a magic cure or a solved mystery. Instead, it paints a vivid, data-driven picture of a growing public health challenge. It tells us that the combination of lung cancer and kidney disease is becoming a more frequent cause of death, and that this burden is not shared equally across the population. The "city" needs to pay attention to its most vulnerable neighborhoods and ensure that the air filters and water treatment plants are working together, not just in isolation, to keep the citizens safe. The authors suggest that doctors need to be more alert to kidney problems in cancer patients and that public health strategies need to be tailored to help the specific groups and places that are struggling the most.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.